Kaposis Sarcoma Market

Kaposi Sarcoma Market (Treatment - Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel - Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Rep Id : TMRGL3354
  • Published On : Aug 2016
  • No. of Pages : 131
  • Category : Healthcare

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights   

2. Assumptions and Research Methodology

3. Executive Summary: Global Kaposi sarcoma market

4. Market Overview
     4.1. Introduction 
     4.2. Key market indicators
     4.3. Regulatory scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Value Chain Analysis

5. Global Kaposi Sarcoma Market, by Treatment 
     5.1. Key Findings 
     5.2. Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
            5.2.1. Chemotherapy
                    5.2.1.1. Liposomal Anthracyclines
                    5.2.1.2. Alkaloids
            5.2.2. Immunotherapy
            5.2.3. HAART
     5.3. Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015

6. Global Kaposi Sarcoma Market, by Distribution Channel
     6.1. Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
            6.1.1. Hospitals
            6.1.2. Cancer Research Institutes
            6.1.3. Multispecialty Clinics
            6.1.4. Ambulatory Surgical Centers
     6.2. Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015

7. Global Kaposi Sarcoma Market, by Region
     7.1. Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
            7.1.1. North America
            7.1.2. Europe
            7.1.3. Asia Pacific
            7.1.4. Latin America
            7.1.5. Middle East and Africa
     7.2. Global Kaposi Sarcoma Market Attractiveness, by Region, 2015

8. Global Kaposi Sarcoma Market, Pipeline Analysis 
     8.1. Overview
     8.2. List of Early Stage Drug Candidates 

9. North America Kaposi Sarcoma Market
     9.1. North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            9.1.1. Chemotherapy 
            9.1.2. Immunotherapy 
            9.1.3. HAART
     9.2. North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            9.2.1. Hospitals
            9.2.2. Cancer Research Institutes
            9.2.3. Multispecialty Clinics
            9.2.4. Ambulatory Surgical Centers
     9.3. North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            9.3.1. U.S.
            9.3.2. Canada
     9.4. Market Attractiveness, by Type of Treatment, 2015
     9.5. Market Attractiveness, by Country, 2015

10. Europe Kaposi Sarcoma Market
     10.1. Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            10.1.1. Chemotherapy 
            10.1.2. Immunotherapy 
            10.1.3. HAART
     10.2. Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            10.2.1. Hospitals
            10.2.2. Cancer Research Institutes
            10.2.3. Multispecialty Clinics
            10.2.4. Ambulatory Surgical Centers
     10.3. EuropeKaposi Sarcoma Market, by Country, (US$), 2014–2024
            10.3.1. U.K.
            10.3.2. Germany
            10.3.3. Rest of Europe
     10.4. Market Attractiveness, by Type of Treatment, 2015
     10.5. Market Attractiveness, by Country, 2015

11. Asia Pacific Kaposi Sarcoma Market
     11.1. Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            11.1.1. Chemotherapy 
            11.1.2. Immunotherapy 
            11.1.3. HAART
     11.2. Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            11.2.1. Hospitals
            11.2.2. Cancer Research Institutes
            11.2.3. Multispecialty Clinics
            11.2.4. Ambulatory Surgical Centers
     11.3. Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            11.3.1. China
            11.3.2. Japan
            11.3.3. India
            11.3.4. Australia
            11.3.5. Rest of Asia Pacific
     11.4. Market Attractiveness, by Type of Treatment, 2015
     11.5. Market Attractiveness, by Country, 2015

12. Latin America Kaposi Sarcoma Market
     12.1. Latin America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            12.1.1. Chemotherapy 
            12.1.2. Immunotherapy 
            12.1.3. HAART
     12.2. Latin America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            12.2.1. Hospitals
            12.2.2. Cancer Research Institutes
            12.2.3. Multispecialty Clinics
            12.2.4. Ambulatory Surgical Centers
     12.3. Latin America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            12.3.1. Brazil
            12.3.2. Mexico
            12.3.3. Rest of Latin America
     12.4. Market Attractiveness, by Type of Treatment, 2015
     12.5. Market Attractiveness, by Country, 2015

13. Middle East and Africa Kaposi Sarcoma Market
     13.1. Middle East and Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            13.1.1. Chemotherapy 
            13.1.2. Immunotherapy 
            13.1.3. HAART
     13.2. Middle East and Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            13.2.1. Hospitals
            13.2.2. Cancer Research Institutes
            13.2.3. Multispecialty Clinics
            13.2.4. Ambulatory Surgical Centers
     13.3. Middle East and Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            13.3.1. U.A.E.
            13.3.2. South African Republic 
            13.3.3. Rest of Middle East and Africa
     13.4. Market Attractiveness, by Type of Treatment, 2015
     13.5. Market Attractiveness, by Country, 2015

14. Global Kaposi Sarcoma Market Analysis, By Services
     14.1. Radiation Therapy
     14.2. Surgery 

15. Competitive Landscape
     15.1. Growth-Share Matrix of Companies, 2015
     15.2. Market Share Analysis, 2015
     15.3. Company Profiles
            15.3.1. Bristol-Myers Squibb Company
                    15.3.1.1. Company Overview
                    15.3.1.2. Business Overview
                    15.3.1.3. Product Portfolio
                    15.3.1.4. Financial Overview
                    15.3.1.5. Recent Developments
            15.3.2. Eli Lilly and Company
                    15.3.2.1. Company Overview
                    15.3.2.2. Business Overview
                    15.3.2.3. Product Portfolio
                    15.3.2.4. Financial Overview
                    15.3.2.5. Recent Developments
            15.3.3. F. Hoffmann-La Roche Ltd.
                    15.3.3.1. Company Overview
                    15.3.3.2. Business Overview
                    15.3.3.3. Product Portfolio
                    15.3.3.4. Financial Overview
                    15.3.3.5. Recent Developments
            15.3.4. GlaxoSmithKline plc
                    15.3.4.1. Company Overview
                    15.3.4.2. Business Overview
                    15.3.4.3. Product Portfolio
                    15.3.4.4. Financial Overview
                    15.3.4.5. Recent Developments
            15.3.5. Johnson & Johnson
                    15.3.5.1. Company Overview
                    15.3.5.2. Business Overview
                    15.3.5.3. Product Portfolio
                    15.3.5.4. Financial Overview
                    15.3.5.5. Recent Developments
            15.3.6. Merck & Co., Inc.
                    15.3.6.1. Company Overview
                    15.3.6.2. Business Overview
                    15.3.6.3. Product Portfolio
                    15.3.6.4. Financial Overview
                    15.3.6.5. Recent Developments
            15.3.7. Pfizer, Inc.  
                    15.3.7.1. Company Overview
                    15.3.7.2. Business Overview
                    15.3.7.3. Product Portfolio
                    15.3.7.4. Financial Overview
                    15.3.7.5. Recent Developments

16. Recommendations

List of Tables

Table 1 Global Kaposi Sarcoma Market, By Type of Treatment Snapshot (2014 - 2024)
Table 2 Global Market, By Distribution Channel, Snapshot (2014 - 2024)
Table 3 Global Market, By Geography Snapshot (2014 - 2024)
Table 4 Global Market, by Type of Treatment, (US$ Mn), 2014–2024
Table 5 Global Market, by Distribution Channel, (US$ Mn), 2014–2024
Table 6 Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
Table 7 Pipeline Analysis
Table 8 North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 9 North America Market, by Distribution Channel, (US$), 2014–    2024
Table 10 North America Market, by Country, (US$), 2014–2024
Table 11 Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 12 Europe Market, by Distribution Channel, (US$), 2014–2024
Table 13 Europe Market, by Country, (US$), 2014–2024
Table 14 Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 15 Asia Pacific Market, by Distribution Channel, (US$), 2014–2024
Table 16 Asia Pacific Market, by Country, (US$), 2014–2024
Table 17 Latin America Kaposi Sarcoma Market, by Type of Treatment (US$), 2014–2024
Table 18 Latin America Market, by Distribution Channel (US$), 2014–2024
Table 19 Latin America Market, by Country (US$), 2014–2024
Table 20 Middle East & Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 21 Middle East & Africa Market, by Distribution Channel, (US$), 2014–2024
Table 22 Middle East & Africa Market, by Country, (US$), 2014–2024
Table 23 Radiotherapy and Surgery (Average cost and Number of procedures)

List of Figures

Figure 1 Market Segmentation
Figure 2 Global Kaposi Sarcoma Market Revenue by Type of Treatment, (US$ Mn), 2014–2024
Figure 3 Global Market Revenue, by Distribution Channel, (US$ Mn), 2014–2024
Figure 4 Global Market Revenue, by Geography, (US$ Mn), 2014–2024
Figure 5 Value Chain Analysis
Figure 6 Global Liposomal Anthracyclines Market for Kaposi Sarcoma, (US$ Mn), 2014–2024
Figure 7 Global Alkaloids Market, (US$ Mn), 2014–2024
Figure 8 Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 9 Global Market Attractiveness, by Distribution Channel, 2015
Figure 10 Global Market Attractiveness, by Region, 2015
Figure 11 North America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 12 North America Market Attractiveness, by Country, 2015
Figure 13 Europe Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 14 Europe Market Attractiveness, by Country, 2015
Figure 15 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 16 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 17 Latin America Market Attractiveness, by Type of Treatment, 2015
Figure 18 Latin America Market Attractiveness, by Country, 2015
Figure 19 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 20 Middle East and Africa Market Attractiveness, by Country, 2015
Figure 21 Growth Share Matrix, By Key Players (2015)
Figure 22 Market Share Analysis by Key Companies (Value %), 2015
Figure 23 Bristol-Myers Squibb Company Financial Overview (US$ Mn), 2013–2015
Figure 24 Bristol-Myers Squibb Company Revenues by Segment, 2015 (%)
Figure 25 Eli Lilly and Company Financial Overview (US$ Mn), 2013–2015
Figure 26 Eli Lilly and Company Human Pharmaceutical Products sub-segment revenues 2015 (%)
Figure 27  F. Hoffmann-La Roche Ltd. Financial Overview (US$ Mn), 2013–2015
Figure 28 F. Hoffmann-La Roche Ltd. Pharmaceutical sub-segment revenues 2015 (%)
Figure 29 GlaxoSmithKline plc Financial Overview (US$ Mn), 2013–2015 
Figure 30 Johnson & Johnson Financial Overview (US$ Mn), 2013–2015
Figure 31 Johnson & Johnson Pharmaceutical sub-segment revenues, 2015 (%)
Figure 32 Merck & Co., Inc. Financial Overview (US$ Mn), 2013–2015
Figure 33 Merck & Co., Inc. Pharmaceutical sub-segment revenues, 2015 (%)
Figure 34 Pfizer, Inc. Financial Overview (US$ Mn), 2013–2015
Figure 35 Pfizer, Inc. Global Vaccines, Oncology, and Consumer Healthcare sub-segment Revenues 2015 (%)

.